Protocol for a prospective observational cohort study of cutaneous leishmaniasis in Ethiopia
Open Access
- 5 October 2023
- journal article
- research article
- Published by National Institute for Health and Care Research in NIHR Open Research
- Vol. 3, 49
Abstract
Background: Cutaneous leishmaniasis (CL) is a skin neglected tropical disease, with an estimated 40,000 new cases each year in Ethiopia. CL causes ulcers, nodules, and plaques on the skin, and in some instances the destruction of the nasopharyngeal mucosa and cartilage. Some CL lesions may heal spontaneously, whilst other lesions may require therapies which are associated with discomfort, adverse effects, prolonged treatment, and a frequent lack of a complete response. Scarring, a sequela of CL, causes permanent disfigurement and is associated with stigma linked with a reduction in health-related quality of life. The choice of treatment for CL is based upon factors including the causative species; the number, extent, size, and location of lesions; and the availability of treatments. The development of robust evidence for CL treatment is hindered by a lack of validated and appropriate outcome measures and few data to support hypothesis-generation and trial design. There is a paucity of prospective data with well-defined treatment outcomes for CL caused by L. aethiopica. Aim: The overall aim of this study is to improve the understanding of the health and economic burden of CL. Methods: We have designed an observational, multi-centre cohort study to examine treatment outcomes for CL in Ethiopia which includes clinical outcomes, laboratory outcomes, patient reported outcome measures, scar assessments and cost effectiveness. We aim to recruit up to 750 participants across two hospital sites. We present here the protocol for this cohort study with a 12-month follow up period for each participant. Conclusions: These data will inform the design of randomized controlled trials to evaluate new treatment strategies, with appropriate economic evaluations. This will help improve evidence-based guidelines and support evidence-led policy decisions, not only in Ethiopia but also globally.Keywords
Funding Information
- National Institute for Health and Care Research (NIHR200125)
This publication has 23 references indexed in Scilit:
- Diagnosis and Treatment of Leishmaniasis: Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA) and the American Society of Tropical Medicine and Hygiene (ASTMH)The American Journal of Tropical Medicine and Hygiene, 2017
- Treatment of Cutaneous Leishmaniasis Caused by Leishmania aethiopica: A Systematic ReviewPLOS Neglected Tropical Diseases, 2016
- The 2016 International League of Dermatological Societies' revised glossary for the description of cutaneous lesionsBritish Journal of Dermatology, 2016
- Cutaneous Leishmaniasis: Recent Developments in Diagnosis and ManagementAmerican Journal of Clinical Dermatology, 2015
- Treatment response of cutaneous leishmaniasis due to Leishmania aethiopica to cryotherapy and generic sodium stibogluconate from patients in Silti, EthiopiaTransactions of the Royal Society of Tropical Medicine and Hygiene, 2012
- Cutaneous and mucocutaneous leishmaniasis in Tigray, northern Ethiopia: clinical aspects and therapeutic concernsTransactions of the Royal Society of Tropical Medicine and Hygiene, 2009
- Treating cutaneous leishmaniasis patients in Kabul, Afghanistan: cost-effectiveness of an operational program in a complex emergency settingBMC Infectious Diseases, 2007
- The psychological impact of cutaneous leishmaniasisClinical and Experimental Dermatology, 2004
- The use of itraconazole in the treatment of leishmaniasis caused by Leishmania aethiopicaTransactions of the Royal Society of Tropical Medicine and Hygiene, 1990
- LIMITED THERAPEUTIC ACTION OF RIFAMPICIN/ISONIAZID AGAINST LEISHMANIA AETHIOPICAThe Lancet, 1981